Stella Pharma Corporation (4888.T)
JPY 555.0
(0.18%)
JPY 555.0
(0.18%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | -876.83 Million | -827.66 Million | -1.08 Billion | -772.81 Million | -913.58 Million |
| Net Income | -760.97 Million | -775.97 Million | -764.08 Million | -656.39 Million | -962 Million |
| Depreciation & Amortization | 35.03 Million | 35.04 Million | 34.13 Million | 31.44 Million | 29.04 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -150.6 Million | -84.9 Million | -350.09 Million | -143.25 Million | 19.53 Million |
| Other non-cash items | 645 Thousand | 1.15 Million | 2.95 Million | 3.23 Million | 962 Million |
| Investing Cash Flow | -9.01 Million | -29.92 Million | -350.56 Million | -22.86 Million | 1.55 Billion |
| Investments in PPE | -10.97 Million | -29.32 Million | -46.26 Million | -22.44 Million | -41.22 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | -304.72 Million | - | - |
| Sales/Maturities of investments | - | - | - | - | 1.6 Billion |
| Other Investing Activities | 1.96 Million | -596 Thousand | 420 Thousand | -420 Thousand | -1.69 Million |
| Financing Cash Flow | 228.35 Million | 291.81 Million | 3.82 Billion | -332.4 Million | -27.57 Million |
| Debt repayment | -160 Million | -160 Million | -160 Million | -160 Million | -27.57 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | -30 Thousand | - | - | - |
| Common Stock Issuance | 388.25 Million | 438.32 Million | 3.61 Billion | 199.92 Million | - |
| Other Financing Activities | 103 Thousand | 13.53 Million | 372.62 Million | -372.32 Million | - |
| Accounts receivables | -16 Million | -42 Million | 38 Million | -55 Million | -12.95 Million |
| Accounts payables | 26.62 Million | 474 Thousand | -13.22 Million | 38.01 Million | 23.8 Million |
| Inventory | -175.66 Million | -166.97 Million | -380.73 Million | -87.32 Million | -25.12 Million |
| Other working capital | 15 Million | 15 Million | 4 Million | -39 Million | 33.8 Million |
| Cash at beginning of period | 2.66 Billion | 3.23 Billion | 837.95 Million | 1.96 Billion | 1.39 Billion |
| Cash at end of period | 2.01 Billion | 2.66 Billion | 3.23 Billion | 837.95 Million | 2 Billion |
| Capital Expenditure | -10.97 Million | -29.32 Million | -46.26 Million | -22.44 Million | -41.22 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -657.49 Million | -565.77 Million | 2.39 Billion | -1.12 Billion | 616.82 Million |
| Free Cash Flow | -887.81 Million | -856.99 Million | -1.12 Billion | -795.25 Million | -954.8 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -294 Million | -760.97 Million | -164 Million | -140 Million | -165 Million | -295 Million |
| Depreciation & Amortization | - | 35.03 Million | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -150.6 Million | - | - | - | - |
| Other non-cash items | 294 Million | 645 Thousand | 164 Million | 140 Million | 165 Million | 295 Million |
| Investing Cash Flow | - | -9.01 Million | - | - | - | - |
| Investments in PPE | - | -10.97 Million | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 1.96 Million | - | - | - | - |
| Financing Cash Flow | - | 228.35 Million | - | - | - | - |
| Debt repayment | - | -160 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 388.25 Million | - | - | - | - |
| Other Financing Activities | - | 103 Thousand | - | - | - | - |
| Accounts receivables | - | -16 Million | - | - | - | - |
| Accounts payables | - | 26.62 Million | - | - | - | - |
| Inventory | - | -175.66 Million | - | - | - | - |
| Other working capital | - | 15 Million | - | - | - | - |
| Cash at beginning of period | - | 2.66 Billion | - | - | - | - |
| Cash at end of period | - | 2.01 Billion | - | - | - | - |
| Capital Expenditure | - | -10.97 Million | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | -657.49 Million | - | - | - | - |
| Free Cash Flow | - | -887.81 Million | - | - | - | - |
CBSH
3695
603318
TKC
0Z62
GOEV